These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA AND Prognosis
303 results:

  • 1. Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation.
    Wang L; Shu M; Zhang Z; Dou X; Xu X; Ma Y; Wen L; Yang X; Chen S
    J Cancer Res Clin Oncol; 2024 Oct; 150(10):465. PubMed ID: 39422784
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [CLAG±DAC regimen in the treatment of refractory/relapsed acute myeloid leukemia].
    Hua WX; Yao WQ; Zhou M; Qi JQ; Kang HZ; Wang RJ; Cai CS; Liu YJ; Wu DP; Han Y
    Zhonghua Xue Ye Xue Za Zhi; 2024 Sep; 45(9):838-843. PubMed ID: 39414607
    [No Abstract]    [Full Text] [Related]  

  • 3. [Prognostic Value of DTA Mutations in Patients with Newly Diagnosed Acute Myeloid leukemia].
    Chen HJ; Cao Y; Miao YJ; Zhou YF; Liu Y; Gu WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):993-998. PubMed ID: 39192388
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Variation characteristics and clinical significance of
    Ma Q; Liu Y; Zhao H; Guo Y; Sun W; Hu R
    Hematology; 2024 Dec; 29(1):2387878. PubMed ID: 39140716
    [No Abstract]    [Full Text] [Related]  

  • 5. Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients.
    Wu Q; Zhang Y; Yuan B; Huang Y; Jiang L; Liu F; Yan P; Cheng J; Long Z; Jiang X
    Cancer Med; 2024 Aug; 13(15):e70102. PubMed ID: 39126219
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Contemporary Management of Acute Myeloid leukemia: A Review.
    Venugopal S; Sekeres MA
    JAMA Oncol; 2024 Oct; 10(10):1417-1425. PubMed ID: 39115831
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China.
    Dou X; Dan C; Zhang D; Zhou H; He R; Zhou G; Zhu Y; Fu N; Niu B; Xu S; Liao Y; Luo Z; Yang L; Zhang H; Xu Y; Zhan Q; Chen W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang Y; Pei L; Wang L
    Int J Cancer; 2024 Dec; 155(12):2253-2264. PubMed ID: 39109820
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The profile and prognostic significance of bone marrow T-cell differentiation subsets in adult AML at diagnosis.
    Sun K; Shi ZY; Wang YZ; Xie DH; Liu YR; Jiang Q; Jiang H; Huang XJ; Qin YZ
    Front Immunol; 2024; 15():1418792. PubMed ID: 39100667
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clonal Hematopoiesis-Associated Gene Mutations Affect Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation in AML Patients.
    Wei X; Huang S; Gu Z; Liu J; Li M; Jin X; Bo J; Li F; Jing Y; Gao X; Dou L; Liu D; Gao C
    Ann Transplant; 2024 Jul; 29():e943688. PubMed ID: 38952007
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
    Hirsch P; Lambert J; Bucci M; Deswarte C; Boudry A; Lambert J; Fenwarth L; Micol JB; Terré C; Celli-Lebras K; Thomas X; Dombret H; Duployez N; Preudhomme C; Itzykson R; Delhommeau F
    Blood Cancer J; 2024 Jun; 14(1):97. PubMed ID: 38871702
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors.
    Tecik M; Adan A
    Curr Treat Options Oncol; 2024 Jun; 25(6):719-751. PubMed ID: 38696033
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
    Othman J; Potter N; Ivey A; Tazi Y; Papaemmanuil E; Jovanovic J; Freeman SD; Gilkes A; Gale R; Rapoz-D'Silva T; Runglall M; Kleeman M; Dhami P; Thomas I; Johnson S; Canham J; Cavenagh J; Kottaridis P; Arnold C; Ommen HB; Overgaard UM; Dennis M; Burnett A; Wilhelm-Benartzi C; Huntly B; Russell NH; Dillon R
    Blood; 2024 Aug; 144(7):714-728. PubMed ID: 38691678
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A Case of Chronic Eosinophilic leukemia with CSF3R-Mutant Clone and Transformed to Secondary Acute Myeloid leukemia.
    Wu Y; Yang X
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623671
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. XPO1 inhibition displays anti-leukemia efficacy against dnmt3a-mutant acute myeloid leukemia via downregulating glutathione pathway.
    Cai X; Liu Y; Li H; Que Y; Xiao M; Wang Y; Wang X; Li D
    Ann Hematol; 2024 Jul; 103(7):2311-2322. PubMed ID: 38519605
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic era.
    Iat A; Loschi M; Benachour S; Calleja A; Chiche E; Sudaka I; Aquaronne D; Ferrero C; Fenwarth L; Marceau A; Fournier E; Dadone-Montaudie B; Cluzeau T
    Cancer Med; 2024 Mar; 13(6):e7103. PubMed ID: 38506267
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
    Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
    Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
    Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. CALCRL knockdown suppresses cancer stemness and chemoresistance in acute myeloid leukemia with FLT3-ITD and DNM3TA-R882 double mutations.
    Tang S; Zhu H; Sheng L; Mu Q; Wang Y; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
    Drug Dev Res; 2024 Feb; 85(1):e22137. PubMed ID: 38349260
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. 5-methylcytosine RNA modification regulators-based patterns and features of immune microenvironment in acute myeloid leukemia.
    Ding Y; Bajpai AK; Wu F; Lu W; Xu L; Mao J; Li Q; Pan Q; Lu L; Wang X
    Aging (Albany NY); 2024 Jan; 16(3):2340-2361. PubMed ID: 38277218
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
    Tefferi A; Vannucchi AM; Barbui T
    Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 16.